Sotatercept

Safety and efficacy of sotatercept (Acceleron Pharma/Merck) vs. placebo at 24 weeks in adults with PAH.

NEW ORLEANS — Sotatercept, a novel activin signaling inhibitor, reduced risk for death and clinical worsening by 84% in patients with pulmonary arterial hypertension compared with placebo, according to results of the STELLAR trial.

SAN FRANCISCO — In this video exclusive, Belinda Natalia Rivera-Lebron, MD, MS, highlights recent updates in the treatment of pulmonary hypertension.

As understanding of pulmonary arterial hypertension grows and novel therapies emerge, the treatment of PAH appears to be entering a new era.

In a preliminary analysis of the ongoing SPECTRA study, patients with pulmonary arterial hypertension treated with sotatercept had improvements in hemodynamics, exercise capacity and 6-minute walk distance.

Sotatercept (Acceleron Pharma) or placebo in adults on background therapy for pulmonary arterial hypertension.

For physicians, pulmonary artery hypertension poses many challenges, including the need for greater awareness and better therapies, according to an expert who spoke with Healio.

Treatment with sotatercept for 24 weeks resulted in a reduction in pulmonary vascular resistance among patients with pulmonary arterial hypertension therapy, according to results of the PULSAR trial.

The Healio editors have compiled a list of the most-read pulmonary arterial hypertension news published in 2020.

The Healio editors have compiled a list of recent updates in the management and treatment of pulmonary hypertension.